
   
   
      
         
            Does_VBZ the_DT Third_NNP World_NNP Deserve_NNP Second-_NNP Class_NNP AIDS_NNP Treatment_NNP ?_.

            This_DT September_NNP ,_, the_DT New_NNP
England_NNP Journal_NNP of_IN Medicine_NNP created_VBD a_DT firestorm_NN when_WRB it_PRP accused_VBD researchers_NNS
of_IN conducting_VBG unethical_JJ experiments_NNS to_TO reduce_VB HIV_NNP in_IN newborns_NNS in_IN Third_NNP World_NNP
countries_NNS ._. The_DT charges_NNS ,_, comparing_VBG the_DT work_NN to_TO the_DT infamous_JJ Tuskegee_NNP experiment_NN ,_,
have_VBP since_IN halted_VBN at_IN least_JJS one_CD HIV_NNP study_NN ._. But_CC a_DT closer_JJR look_NN suggests_VBZ that_IN the_DT
critics_NNS suffer_VBP from_IN an_DT ethical_JJ blindness_NN of_IN their_PRP$ own_JJ ._.

            The_DT
studies_NNS in_IN question_NN are_VBP seeking_VBG low-cost_JJ ways_NNS to_TO prevent_VB HIV-positive_NNP pregnant_JJ
mothers_NNS from_IN transmitting_VBG the_DT virus_NN to_TO their_PRP$ newborns_NNS ._. A_DT breakthrough_NN 1994_CD
study_NN found_VBD a_DT drug_NN regimen_NN that_IN dramatically_RB reduced_VBN HIV-transmission_NNP
rates--from_JJ 26_CD percent_NN of_IN births_NNS to_TO 8_CD percent_NN ._. Doctors_NNS in_IN industrialized_VBN
nations_NNS rapidly_RB adopted_VBD the_DT strategy_NN as_IN the_DT standard_NN of_IN care_NN ._. At_IN $_$ 800_CD a_DT pop_NN ,_,
however_RB ,_, poor_JJ countries_NNS ca_MD n't_RB afford_VB the_DT full_JJ regimen_NN ._. It_PRP 's_VBZ also_RB too_RB complex_JJ ._.
Mothers_NNS must_MD take_VB AZT_NNP ,_, an_DT antiviral_JJ ,_, five_CD times_NNS a_DT day_NN during_IN pregnancy_NN ;_: receive_VB
intravenous_JJ AZT_NNP during_IN labor_NN ;_: forgo_VB breastfeeding_VBG to_TO prevent_VB transmission_NN in_IN
milk_NN ;_: and_CC give_VB their_PRP$ babies_NNS liquid_JJ AZT_NNP four_CD times_NNS daily_JJ for_IN six_CD weeks_NNS ._.

            Sixteen_NNP studies_NNS to_TO find_VB simpler_JJR ,_, cheaper_JJR methods_NNS are_VBP now_RB
testing_VBG everything_NN from_IN vitamin_NN A_DT to_TO a_DT shorter_JJR course_NN of_IN oral_JJ AZT_NNP ._. The_DT U_NNP ._. S_NNP ._.
Centers_NNPS for_IN Disease_NNP Control_NNP and_CC Prevention_NNP and_CC the_DT National_NNP Institutes_NNPS of_IN
Health_NNP fund_NN nine_CD of_IN these_DT ,_, involving_VBG 12_CD ,_, 211_CD women_NNS in_IN Uganda_NNP ,_, Thailand_NNP ,_,
Tanzania_NNP ,_, and_CC elsewhere_RB ._. In_IN every_DT study_NN ,_, some_DT mothers_NNS must_MD serve_VB as_IN a_DT
comparison_NN group_NN ,_, and_CC that_DT 's_VBZ where_WRB the_DT trouble_NN begins_VBZ ._. For_IN two_CD years_NNS
researchers_NNS debated_VBN whether_IN to_TO compare_VB new_JJ therapies_NNS to_TO the_DT full_JJ AZT_NNP regimen_NN or_CC
to_TO no_DT treatment_NN at_IN all_DT ._. In_IN the_DT end_NN ,_, 15_CD of_IN the_DT 16_CD trials_NNS gave_VBD the_DT comparison_NN
group_NN a_DT placebo_NN ._.

            In_IN their_PRP$
article_NN reopening_VBG the_DT debate_NN ,_, Peter_NNP Lurie_NNP and_CC Sidney_NNP Wolfe_NNP ,_, doctors_NNS with_IN Ralph_NNP
Nader_NNP 's_POS Public_NNP Citizen_NNP Health_NNP Research_NNP Group_NNP ,_, condemned_VBD these_DT 15_CD trials_NNS ._.
Researchers_NNS giving_VBG placebos_NNS ,_, they_PRP said_VBD ,_, were_VBD knowingly_RB killing_VBG children_NNS ._. They_PRP
quoted_VBD the_DT Helsinki_NNP Declaration_NNP of_IN the_DT World_NNP Health_NNP Organization_NNP :_: "_'' In_IN any_DT
medical_JJ study_NN ,_, every_DT patient--including_JJ those_DT of_IN a_DT control_NN group_NN ,_, if_IN
any--should_JJ be_VB assured_VBN of_IN the_DT best_RBS proven_VBN diagnostic_JJ and_CC therapeutic_JJ methods_NNS ._. "_''
To_TO them_PRP ,_, the_DT only_RB valid_JJ question_NN is_VBZ how_WRB new_JJ treatments_NNS compare_VBP to_TO the_DT complex_JJ
AZT_NNP treatment_NN ._.

            
The_DT Journal_NNP 's_POS editorial_NN was_VBD even_RB more_JJR
pointed_VBD ._. It_PRP accused_VBD HIV_NNP researchers_NNS of_IN "_'' self-serving_JJ justification_NN ,_, "_'' and_CC
likened_VBD their_PRP$ studies_NNS to_TO the_DT Tuskegee_NNP experiment_NN ._. Conducted_NNP by_IN the_DT U_NNP ._. S_NNP ._. Public_NNP
Health_NNP Service_NNP from_IN 1932_CD to_TO 1972_CD ,_, that_DT study_NN left_VBD 412_CD black_JJ syphilitic_JJ men_NNS
untreated--even_JJ after_IN penicillin_NN became_VBD widely_RB available--in_JJ an_DT attempt_NN to_TO
determine_VB the_DT natural_JJ history_NN of_IN syphilis_NNS ._. The_DT experiment_NN ,_, halted_VBD only_RB after_IN
exposure_NN by_IN journalists_NNS ,_, remains_VBZ a_DT textbook_NN example_NN of_IN unethical_JJ ,_, racist_JJ
research_NN ._.

            The_DT
Journal_NNP 's_POS charges_NNS made_VBD front-page_JJ news_NN ._. Only_RB a_DT pre-publication_JJ leak_NN
allowed_VBD NIH_NNP director_NN Harold_NNP Varmus_NNP and_CC CDC_NNP director_NN David_NNP Satcher_NNP to_TO publish_VB
their_PRP$ indignant_NN defense_NN the_DT next_JJ week_NN ._. In_IN an_DT unlikely_JJ spectacle_NN ,_, Republican_NNP
Sen_NNP ._. Dan_NNP Coats_NNP stood_VBD up_RP for_IN poor_NNP Africans_NNPS to_TO oppose_VB Satcher_NNP 's_POS nomination_NN for_IN
surgeon_NN general_JJ ._. (_( Ultimately_RB ,_, the_DT Senate_NNP Labor_NNP Committee_NNP approved_VBD Satcher_NNP 12_CD to_TO
5_CD ._. )_) Johns_NNP Hopkins_NNP researchers_NNS suspended_VBD an_DT Ethiopian_JJ study_NN with_IN placebos_NNS ._. Other_JJ
suspensions_NNS may_MD follow_VB ._.

            Ethics_NNP ,_, the_DT critics_NNS insist_VBP ,_, demand_NN that_IN U_NNP ._. S_NNP ._. researchers_NNS
provide_VBP the_DT American_JJ standard_NN of_IN care_NN to_TO Third_NNP World_NNP subjects_NNS to_TO avoid_VB
exploitation_NN ._. But_CC they_PRP do_VBP n't_RB ._. The_DT critics_NNS '_POS arguments_NNS seem_VBP reasonable_JJ only_RB if_IN
they_PRP ignore_VBP the_DT facts_NNS :_:

            
               This_DT is_VBZ n't_RB Tuskegee_NNP ._.
In_IN Tuskegee_NNP ,_, doctors_NNS sought_VBD no_DT public_JJ review_NN ,_, had_VBD no_DT clearly_RB beneficial_JJ aim_NN ,_,
and_CC deceived_VBD patients_NNS into_IN getting_VBG no_DT treatment_NN ._. By_IN comparison_NN ,_, the_DT HIV_NNP trials_NNS
were_VBD reviewed_VBN extensively_RB and_CC approved_VBN by_IN local_JJ governments_NNS and_CC the_DT World_NNP
Health_NNP Organization_NNP ._. The_DT experimental_JJ therapies_NNS may_MD offer_VB great_JJ benefit_NN ._. And_CC
some_DT subjects_NNS receive_VBP placebos_NNS because_IN ,_, unlike_IN penicillin_NN for_IN Alabama_NNP ,_, the_DT full_JJ
AZT_NNP regimen_NN is_VBZ out_IN of_IN reach_NN for_IN poor_JJ countries_NNS ._.

            
               The_DT complete_JJ AZT_NNP regimen_NN
is_VBZ n't_RB coming_VBG ._. By_IN 2000_CD ,_, 6_CD million_CD pregnant_JJ women_NNS in_IN developing_VBG nations_NNS will_MD
carry_VB HIV_NNP ._. Critics_NNS are_VBP right_RB that_IN a_DT complex_JJ AZT_NNP regimen_NN would_MD be_VB best_JJS for_IN them_PRP ._.
It_PRP is_VBZ the_DT standard_NN of_IN care_NN ._. So_RB are_VBP CAT_NNP scanners_NNS and_CC heart-bypass_JJ surgery_NN ._. But_CC
poor_JJ countries_NNS are_VBP n't_RB going_VBG to_TO get_VB any_DT of_IN these_DT ._. Cost_NN is_VBZ a_DT big_JJ reason--these_JJ
countries_NNS typically_RB spend_VBP under_IN $_$ 20_CD per_IN person_NN on_IN health_NN care_NN annually_RB ._. But_CC
even_RB if_IN Glaxo_NNP Wellcome_NNP gave_VBD away_RB the_DT drugs_NNS ,_, the_DT complete_JJ regimen_NN is_VBZ still_RB
infeasible_JJ in_IN much_JJ of_IN Africa_NNP and_CC south_RB Asia_NNP ._. There_RB ,_, tubing_VBG and_CC skills_NNS for_IN
intravenous_JJ AZT_NNP are_VBP scarce_JJ ._. The_DT governments_NNS ca_MD n't_RB afford_VB to_TO give_VB moms_NNS formula_NN
to_TO stop_VB them_PRP from_IN breast-feeding_JJ ._. Mothers_NNS also_RB live_VBP too_RB far_RB from_IN doctors_NNS to_TO get_VB
therapy_NN early_RB in_IN pregnancy_NN and_CC to_TO keep_VB up_RP with_IN necessary_JJ monitoring_NN ._.

            
               Something_NN may_MD be_VB better_JJR
than_IN nothing_NN ._. If_IN trials_NNS compared_VBD low-cost_JJ therapy_NN to_TO the_DT complete_JJ AZT_NNP
regimen_NN it_PRP 's_VBZ likely_JJ that_IN the_DT new_JJ regimens_NNS will_MD prove_VB less_RBR effective_JJ ._. But_CC
such_JJ results_NNS are_VBP useless_JJ ,_, since_IN the_DT full_JJ treatment_NN is_VBZ not_RB an_DT option_NN ._.
Without_IN a_DT placebo_NN group_NN ,_, we_PRP still_RB wo_MD n't_RB know_VB if_IN any_DT of_IN the_DT treatments_NNS are_VBP
better_JJR than_IN nothing_NN and_CC therefore_RB worth_JJ giving_NN ._.

            
               We_PRP 've_VBP
been_VBN here_RB before_RB ._. These_DT issues_NNS are_VBP n't_RB new_JJ ._. Cheap_JJ oral_JJ hydration_NN ,_, for_IN
example_NN ,_, has_VBZ been_VBN studied_VBN and_CC used_VBN to_TO treat_VB dehydration_NN for_IN diarrheal_NN illness_NN
in_IN developing_VBG countries_NNS ._. It_PRP works--but_JJ not_RB as_RB well_RB as_IN intravenous_JJ hydration_NN ._.
Far_RB from_IN condemning_VBG its_PRP$ use_NN as_IN unethical_JJ ,_, however_RB ,_, doctors_NNS have_VBP embraced_VBN oral_JJ
hydration_NN as_IN the_DT model_NN of_IN locally_RB appropriate_JJ therapy_NN ._. Similarly_RB ,_, poor_JJ
countries_NNS wo_MD n't_RB adopt_VB a_DT new_JJ rotavirus_JJ vaccine_NN ,_, despite_IN 600_CD ,_, 000_CD deaths_NNS a_DT year_NN
from_IN diarrhea_NN caused_VBN by_IN the_DT bug_NN ._. Inoculating_NNP every_DT child_NN at_IN $_$ 30_CD a_DT dose_NN would_MD
divert_VB scarce_JJ resources_NNS from_IN even_RB better_JJR uses_NNS ._.

            The_DT core_NN issue_NN is_VBZ whether_IN it_PRP is_VBZ ethical_JJ for_IN Americans_NNPS to_TO
conduct_VB Third_NNP World_NNP studies_NNS seeking_VBG therapies_NNS cheaper_RBR and_CC perhaps_RB inferior_JJ to_TO
our_PRP$ own_JJ ._. It_PRP can_MD be_VB ,_, but_CC only_RB if_IN :_: 1_LS )_) Subjects_NNP get_VB the_DT best_JJS care_NN feasible_JJ locally_RB
(_( they_PRP do_VBP )_) ._. 2_LS )_) It_PRP 's_VBZ done_VBN for_IN local_JJ benefit_NN (_( measuring_VBG a_DT new_JJ therapy_NN against_IN
placebo_NN is_VBZ n't_RB useful_JJ for_IN the_DT West_NNP ;_: we_PRP 'd_MD switch_VB only_RB if_IN it_PRP were_VBD as_RB effective_JJ as_IN
the_DT more_RBR complex_JJ therapy_NN )_) ._. 3_LS )_) The_DT new_JJ regimens_NNS are_VBP themselves_PRP feasible_JJ (_( at_IN
costs_NNS from_IN pennies_NNS to_TO $_$ 60_CD per_IN patient_NN ,_, they_PRP seem_VBP to_TO be_VB )_) ._. 4_LS )_) The_DT American_JJ
standard_NN is_VBZ unavailable_JJ for_IN legitimate_JJ reasons_NNS (_( I_NN 've_VBP already_RB mentioned_VBN all_PDT the_DT
obstacles_NNS )_) ._.

            For_IN the_DT folks_NNS at_IN Public_NNP
Citizen_NNP ,_, this_DT last_JJ criterion_NN really_RB sticks_VBZ in_IN their_PRP$ craws_NNS ._. It_PRP offends_VBZ them_PRP to_TO
see_VB researchers_NNS accepting_VBG the_DT high_JJ cost_NN of_IN American_JJ medical_JJ care_NN as_IN a_DT given_VBN ._.
Could_MD drug_NN companies_NNS lower_JJR their_PRP$ costs_NNS ?_. Maybe_RB ,_, maybe_RB not_RB ._. But_CC this_DT is_VBZ not_RB the_DT
way_NN to_TO debate_VB free-market_JJ pricing_NN of_IN technology_NN ._. Do_VBP n't_RB stop_VB the_DT research_NN ._.
Acknowledging_NNP reality_NN is_VBZ n't_RB unethical_JJ ,_, but_CC ignoring_VBG it_PRP can_MD be_VB ._.

         
      
   
